Abstract
A total of 66 bladder cancer patients were studied to establish if relationships exist between HER-2/neu alteration and pathological stage and grade and to define a subgroup of patients with poor prognosis in terms of time to recurrence, time to progression and survival. Tumor and healthy tissue specimens were analyzed for HER-2/neu DNA amplification and protein over-expression by Southern and Western blot techniques. Results were analysed statistically. 13% cases were amplified and 39% over-expressed. HER- 2/neu alterations were not significantly associated with pathological staging or tumor grading. Multifocal tumors had a higher percentage and more over- expression than monofocal tumors. Actuarial analyses did not show a significant correlation between HER-2/neu amplification, over-expression and clinical outcome. Clinical assessment of HER-2/neu status showed this gene is not related to tumor relapse, progression or patient survival.
| Original language | English |
|---|---|
| Pages (from-to) | 129-134 |
| Number of pages | 6 |
| Journal | Acta Urologica Italica |
| Volume | 13 |
| Issue number | 2 |
| Publication status | Published - 1999 |
Keywords
- Bladder cancer
- HER-2/neu
- Oncogene
ASJC Scopus subject areas
- Urology